What do medical professionals want to change about radiotherapy?

According to the Mayo Clinic, more than half of all people with cancer receive radiation therapy as part of their cancer treatment. Although radiotherapy has become a more increasingly common aspect of the cancer treatment process, there are still potential challenges that oncology professionals face in the radiotherapy treatment process. Two primary areas of concern are healthcare worker’s overall time availability and accuracy of contours in the radiotherapy process.

What are common challenges in the radiotherapy process?

Taipei Veterans General Hospital defines clinical target volume delineation (TVD) as, “all potential areas at risk for microscopic tumor involvement either by direct extension or nodal spread.” A literature review published in 2017 by the Frontiers in Oncology journal focused on reviewing literature related to TVD variability and its impact on dosimetry and clinical outcomes. The review found that, “TVD variability is a significant problem in radiotherapy both within and outside clinical trials.” The accuracy of contouring directly affects the TVD variability, and therefore is of concern to oncology departments.

Image of contour from MVision's 1.2.1 update
MVision AI’s recent Segmentation Service Update 1.2.1, included an update on the Abdomen § Thorax Model (including 26 OARS and SABR protocol structures), as seen in this image.

Additionally, the radiotherapy process can be time consuming for both the patient and the oncology department as a whole. Not only can the contouring process be rather cumbersome: the patient waiting time can be slow-moving as well. According to Cancer Research UK, patients may have to wait up to 2 months (62 days) to receive proper cancer treatment.

The Poll

MVision AI always seeks to further understand and address radiotherapy-related needs and concerns of healthcare professionals. In order to do so, MVision AI conducted a poll, via various social media platforms, asking the question: if you could change one thing about your clinic’s radiotherapy process, what would it be? Respondents were given the opportunity to provide their own, original response, or to select an answer from the following options: the time spent on contouring; the accuracy of the contouring; the waiting time for patients; or more time to help patients. 

The MVision AI team really appreciated all of the responses from medical professionals around the globe. We received a total of 116, well thought, responses. The results of the poll indicated that:  

  • 41% of respondents wanted to change: the accuracy of contouring
  • 28% wanted to change the waiting time for patients
  • 18% wanted to change the time spent on contouring 
  • 10% wanted more time to help patients 
  • 3% provided their own responses

The minority of respondents provided their own, original responses (3%), including: more time to focus on the follow-up and side effects, and to reduce the spent on the quality assurance of the Linear Accelerator, or LINAC (the device commonly used for external beam radiation treatments for patients with cancer). 

Results from the poll.
Results from the recent poll are depicted in this image.

MVision AI assists medical professionals with overcoming challenges in the radiotherapy treatment process.  

MVision AI’s GDPR and guideline compliant, automatic segmentation and contouring software uses breakthrough deep learning technology to power its artificial intelligence (AI) algorithms. MVision assists oncology departments worldwide in improving contour accuracy. The MVision team is aware of current challenges surrounding inter-observer variation in manual contouring. We replace variation with high consistency. This helps to limit adverse effects related to errors in delineation of structures. 

MVision also helps save healthcare professionals time and helps to reduce patient waiting times. Mvision’s fully automated 3D organ models that are delivered within minutes, as opposed to hours of manual work. This helps medical professionals focus on more complex delineation tasks; stop wasting limited resources; reduce patient waiting times; have more time to focus on the follow-up and side effects; and gives oncologists more time to spend with their patients. 

MVision is happy to be at your service 

If you are interested in learning more about MVision’s guideline-based, timesaving, consistent, and GDPR compliant services, visit our website and follow us on LinkedIn

You are more than welcome to contact us: 

c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.

Tel: +358 (0) 40 5489 229

Email: info@mvision.ai

For media inquiries

Tel: +358 40 500 7915

Email: pr@mvision.ai

Sources

ACR, RSNA and. “Linear Accelerator.” Radiologyinfo.org, RadiologyInfo.org, 18 June 2018, www.radiologyinfo.org/en/info/linac. 

“Cancer Waiting Times.” Cancer Waiting Times | Cancer Information | Cancer Research UK, 6 Jan. 2020, www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/access-to-treatment/waiting-times-after-diagnosis. 

Chang, Amy Tien Yee, et al. “Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials.” Frontiers in Oncology, Frontiers Media S.A., 25 Sept. 2017, www.ncbi.nlm.nih.gov/pmc/articles/PMC5622143/. 

“Radiation Therapy.” Mayo Clinic, Mayo Foundation for Medical Education and Research, 1 July 2020, www.mayoclinic.org/tests-procedures/radiation-therapy/about/pac-20385162. 

“Taipei Veterans General Hospital Practices Guidelines Oncology Oral Cavity Cancer Version – Ppt Download.” SlidePlayer, slideplayer.com/slide/11628819/.

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

13.12.2024

Saad Ullah Akram Appointed as CEO of MVision AI

Helsinki, Finland – MVision AI, a leading provider of AI-powered solutions for radiation therapy treatment planning, announces the appointment of Saad Ullah Akram as its new Chief Executive Officer. Known for its commitment to streamlining workflows and enhancing treatment quality in cancer care, MVision AI is embarking on an exciting…

Press Releases

20.11.2024

MVision AI Ranked Among the Top 10 in Deloitte Technology Fast 50 Finland for 2024

Helsinki, Finland, 20 November 2024 – MVision AI, a leading innovator in AI-driven solutions for oncology, is proud to announce its recognition among the top ten companies in the Deloitte Technology Fast 50 Finland 2024 ranking. This prestigious award acknowledges MVision AI's rapid growth and its mission-driven advancements in making…

Press Releases

7.11.2024

Safe and Ethical AI in Radiation Oncology: Regulations and MVision’s Compliance

Technology is evolving, and the same applies to Radiation Oncology. New ways and new tools require new rules. Artificial intelligence (AI)  brings tremendous potential, so the world has to learn how to get the best of it, safely.  Al systems identified as high-risk have to comply with strict requirements, including…

Articles